ArticleFrontiers in clinical diabetes and healthcare2025
Association of serum levels of soluble triggering receptor expressed on myeloid cells-1 with endothelial dysfunction in patients with type 2 diabetes.
Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The correlation between TREM-1 and vascular complications in patients with type 2 diabetes was a subject of debate. This study aimed to investigate the potential correlation between TREM-1 and flow-mediated dilatation (FMD) in patients with type 2 diabetes mellitus. Methods: In this retrospective cohort research, 201 patients with type 2 patients diabetes were enrolled. The FMD Vascular Endothelial Cell Function Test Instrument was used to evaluate endothelial dysfunction. The serum levels of TREM-1 were measured using enzyme-linked immunosorbent assay. The Spearman correlation test was employed to determine the association between TREM-1 and FMD. Univariable logistic regression analysis was conducted to assess the relationship between TREM-1 and FMD. Additionally, receiver operating characteristic curve analysis was used to determine the TREM-1's predictive value. The statistical significance was evaluated using a two-tailed P-value >0.05. Results: The study involved dichotomizing diabetic patients into low FMD (n = 138) and high FMD (n = 63) groups. The results showed that serum TREM-1 levels were significantly higher in the low FMD group than in the high FMD group (33.6 vs 58.0 pg/ml, P<0.001). A univariate logistic regression analysis revealed a statistically significant association between FMD and TREM-1 (P<0.05). The area under the curve for the receiver operating characteristic curve for model 1 (TREM-1) analysis was 0.66 (0.58-0.74) (P 0.001). Using the criteria of maximal Youden index, the threshold value for TREM-1 was found to be 38.16 ng/ml. This value showed a sensitivity of 75.4% and a specificity of 54% in predicting endothelial dysfunction in patients with type 2 diabetes mellitus. Conclusion: Serum TREM-1 levels were associated with FMD, indicating that TREM-1 could be a valuable biomarker for assessing endothelial function in T2DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.